Leukemia

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

What it’s like having a “second birthday” after receiving a bone marrow transplant for my AML.

From Patrick Swayze’s widow recalling his pancreatic cancer diagnosis to Demi Moore speaking about her aunt’s courage during cancer, here’s what’s going on in the oncology space this week.

From WWE champion Roman Reigns sharing about his leukemia status to Arizona rep. Raúl Grijalva announcing diagnosis, here’s what’s going on in the oncology space this week.

From Fortnight player, “Ninja” announcing his melanoma diagnosis to an LSU quarterback sporting the name of his teammate with brain cancer, here’s what’s going on in the oncology space this week.

Besponsa provides another — and potentially more effective — option outside of traditional chemotherapy for pediatric patients with relapsed or refractory B-ALL.

Patients taking Tibsovo to treat MDS or AML may want to discuss the appropriate medications to treat and prevent infections, an expert said.

The Food and Drug Administration granted an accelerated approval to Iclusig, described as the new “standard of care” for adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.

Some patients are forced to deal with “infuriating” attempts at exploitation while navigating their disease.

The Food and Drug Administration approved Besponsa for pediatric patients aged 1 and older with relapsed or refractory CD22-positive, B-cell precursor ALL.

“Waiting” described the waiting room at Children’s Hospital to get my chemotherapy. “My Days” was a remembrance of the year I was diagnosed with leukemia.

The first patient has been enrolled in a clinical trial evaluating a reduced dose of post-transplant immunosuppressive chemotherapy cyclophosphamide for patients with blood cancers.

From Ben Lanzarone of “Happy Days” and “Grease” dying of lung cancer to “Good Morning America’s” Michael Strahan providing an update on his daughter’s medulloblastoma treatment, here’s what’s happening in the oncology space this week.

From International Childhood Cancer Day to an Ivory Coast soccer player making a victorious comeback after testicular cancer, here’s what is happening in the oncology space this week.

When people tell me I "fought cancer," I disagree. I believe I endured cancer.

Newly diagnosed patients with FLT3-mutated acute myeloid leukemia showed improvements after receiving crenolanib plus chemotherapy in a recent study.

The Food and Drug Administration granted a priority review to Blincyto for the treatment of early-stage CD19-positive B-cell acute lymphoblastic leukemia.

The Food and Drug Administration is requesting that CAR-T cell therapies now come with a Boxed Warning about secondary malignancies that have been reported in patients who undergo these treatments.

Financial burdens from medical costs negatively affect quality of life in patients who have received stem cell transplants, recent research showed.

Newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia had better outcomes when receiving Scemblix, compared with a different TKI, a study found.

Patients with Down syndrome and B-cell acute lymphoblastic leukemia tended to have higher rates of treatment-related deaths and poorer overall survival than those without Down syndrome.

Among patients with relapsed chronic lymphocytic leukemia (CLL) who expressed frequent baseline BTK mutations, responses on the non-covalent BTK inhibitor Jaypirca remained high, according to data presented at the 2023 ASH Annual Meeting.

A comparison of Scemblix (asciminib) and Bosulif (bosutinib) demonstrated greater efficacy and safety/tolerability with asciminib for patients with chronic phase chronic myeloid leukemia.

Recently approved by the FDA for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Jaypirca “represents a meaningful advance” in treatment, as one expert explained.

Children and adults with relapsed/refractory KMT2A rearranged acute leukemia may obtain promising response rates with revumenib, a novel targeted therapy.

A novel cell therapy demonstrated early efficacy and an acceptable safety profile in patients with graft-versus-host disease undergoing haploidentical stem cell transplantation.

The three-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid-refractory or dependent chronic graft-versus-host disease benefited more with Jakafi compared with the best available treatment.

Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies.

Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.

As Billy Bean, MLB VP, revealed a cancer diagnosis and Toronto Blue Jays sportscaster, Jamie Campbell showed pre-skin cancer photo, here is what’s happening in the oncology space this week.